Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | POLG | P54098 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082373 | 0.92 | FAP (0.51) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| SCHEMBL5082989 | 0.91 | FAP (0.51) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| SCHEMBL5086069 | 0.82 | PI4KA (0.43) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| SCHEMBL5082477 | 0.80 | FAP (0.39) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5083031 | 0.77 | FAP (0.37) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5086122 | 0.76 | TAS1R3 (0.39) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5086376 | 0.73 | PI4KA (0.44) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| SCHEMBL5082287 | 0.73 | PI4KA (0.44) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| SCHEMBL2449991 | 0.71 | PI4KA (0.56) | FAPCYP3A4PI4KAPI4K2BPI4K2A | |
| Tenofovir Disoproxil SCHEMBL22157305 | 0.69 | FAP (0.93) | FAPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | FAP 4556/4885CYP3A4 941/4885PI4KA 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.